ClinicalTrials.gg
CompletedNCT00991458Updated Jul 11, 2013Results posted

Study of Cyclosporine in Post-LASIK Patients

A Phase 2 interventional study of Cyclosporine 0.010% eye drops and Cyclosporine 0.005% eye drops in Laser In Situ Keratomileusis, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-07-11.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.

02

Conditions studied

  • Laser In Situ Keratomileusis
03

In context

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is scheduled for bilateral LASIK surgery
  • Patient is in good general health
  • Eye glasses prescription of -1 to -8

Exclusion criteria

Exclusion Criteria:

  • Significant Dry Eye
  • Presence of eye disease
  • Uncontrolled systemic disease
  • Previous use of RESTASIS®
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
621 participants (actual)

Study arms

  • Experimental
    Cyclosporine 0.010% eye drops

    Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

    Drug: Cyclosporine 0.010% eye drops

  • Experimental
    Cyclosporine 0.005% eye drops

    Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

    Drug: Cyclosporine 0.005% eye drops

  • Placebo comparator
    Placebo (Vehicle for Cyclosporine)

    Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

    Drug: Placebo (Vehicle for Cyclosporine)

Interventions

  • Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

  • Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

  • DrugPlacebo (Vehicle for Cyclosporine)

    Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

06

What researchers measure

Primary outcomes

  1. Time to Cure

    Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.

    Time frame: 6 Months

Secondary outcomes

  1. Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment

    The time to the worst outcome post-LASIK surgery in tear film stability is assessed using the Ocular Scatter Index (OSI). The OSI is calculated by an instrument which takes images of the eye over time. OSI values ≥3.0 indicate lower tear film quality resulting in a loss of visual acuity. The worst outcome post-LASIK surgery is defined as the shortest time to OSI ≥3 across both eyes and post-LASIK surgery months 3 to 6.

    Time frame: Months 3 to 6

  2. Percentage of Patients With Cumulative Poor Vision

    Cumulative Poor Vision is determined binocularly per patient (using both eyes at the same time) from the Poor Vision question on the Ocular Surface Disease Index (OSDI) questionnaire. Severity of poor vision is graded on a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half of the time, 3 = most of the time, 4 = all of the time). Cumulative poor vision is defined as at least one poor vision score ≥ 1 beginning at Month 3 post-LASIK.

    Time frame: Month 3, Month 4, Month 5, Month 6

  3. Worst Outcome Post-LASIK Surgery in Reading Speed Assessment

    Reading speed is determined using the MNREAD™ Reading Card. The MNREAD™ reading card is designed to simulate a normal every day reading scenario using binocular vision (both eyes at the same time). The MNREAD™ Reading speed is calculated as (60) X \[Number of words on card - (reading errors)\]/ (number of seconds until the card is read). The worst outcome is defined as the smallest number of words per minute across post-LASIK surgery months 3 to 6.

    Time frame: Months 3 to 6

07

Results

Posted Jul 11, 2013

Participant flow

Participant flow — Overall Study
MilestoneCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Started207209205
Completed187181180
Not completed202825

Outcome measures

PrimaryTime to Cure

Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.

Time frame:
6 Months
Reported as:
Median · Days
Time to Cure
DaysCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Time to Cure189.0 (181.0 to NA)194.0 (181.0 to 196.0)189.0 (180.0 to NA)
SecondaryTime to Worst Outcome Post-LASIK Surgery in Tear Film Assessment

The time to the worst outcome post-LASIK surgery in tear film stability is assessed using the Ocular Scatter Index (OSI). The OSI is calculated by an instrument which takes images of the eye over time. OSI values ≥3.0 indicate lower tear film quality resulting in a loss of visual acuity. The worst outcome post-LASIK surgery is defined as the shortest time to OSI ≥3 across both eyes and post-LASIK surgery months 3 to 6.

Time frame:
Months 3 to 6
Reported as:
Mean · Seconds
Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment
SecondsCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment11.2 ± 4.2412.0 ± 4.5111.5 ± 4.39
SecondaryPercentage of Patients With Cumulative Poor Vision

Cumulative Poor Vision is determined binocularly per patient (using both eyes at the same time) from the Poor Vision question on the Ocular Surface Disease Index (OSDI) questionnaire. Severity of poor vision is graded on a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half of the time, 3 = most of the time, 4 = all of the time). Cumulative poor vision is defined as at least one poor vision score ≥ 1 beginning at Month 3 post-LASIK.

Time frame:
Month 3, Month 4, Month 5, Month 6
Reported as:
Number · Percentage of Patients
Percentage of Patients With Cumulative Poor Vision
Percentage of PatientsCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Month 315.018.719.0
Month 417.922.523.9
Month 521.726.324.9
Month 623.726.826.3
SecondaryWorst Outcome Post-LASIK Surgery in Reading Speed Assessment

Reading speed is determined using the MNREAD™ Reading Card. The MNREAD™ reading card is designed to simulate a normal every day reading scenario using binocular vision (both eyes at the same time). The MNREAD™ Reading speed is calculated as (60) X \[Number of words on card - (reading errors)\]/ (number of seconds until the card is read). The worst outcome is defined as the smallest number of words per minute across post-LASIK surgery months 3 to 6.

Time frame:
Months 3 to 6
Reported as:
Mean · Words Per Minute (WPM)
Worst Outcome Post-LASIK Surgery in Reading Speed Assessment
Words Per Minute (WPM)Cyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Worst Outcome Post-LASIK Surgery in Reading Speed Assessment173.0 ± 40.17173.7 ± 42.18167.4 ± 45.21

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine 0.010% Eye Drops—2/207 (1%)78/207 (37.7%)
Cyclosporine 0.005% Eye Drops—0/209 (0%)66/209 (31.6%)
Placebo (Vehicle for Cyclosporine)—3/205 (1.5%)66/205 (32.2%)
Most frequent serious events
Most frequent serious events
EventCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/1150/1181/105
PregnancyPregnancy, puerperium and perinatal conditions0/1150/1181/105
Haemorrhagic Ovarian CystReproductive system and breast disorders1/1150/1180/105
Refraction DisorderEye disorders0/2070/2091/205
Clavicle FractureInjury, poisoning and procedural complications1/2070/2090/205
Most frequent other events
Most frequent other events
EventCyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)
Dry EyeEye disorders52/20748/20947/205
Punctate KeratitisEye disorders13/20711/20910/205
Vision BlurredEye disorders13/2077/2099/205

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)Total
<30 years686977214
30 to 40 years1109792299
>40 years294336108
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine 0.010% Eye DropsCyclosporine 0.005% Eye DropsPlacebo (Vehicle for Cyclosporine)Total
Female115118105338
Male9291100283
08

Study locations

1 site
  • Overland Park, Kansas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years 3 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2009
First posted
Oct 8, 2009
Start
Oct 2009
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results delay requested
Apr 2, 2012
Results first posted
Jul 11, 2013
Last update
Jul 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00991458
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 8, 2009
Start date
Oct 2009
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Jul 11, 2013
Last update
Jul 11, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion